Navigation Links
No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
Date:9/21/2012

SACRAMENTO, Calif., Sept. 21, 2012 /PRNewswire/ -- According to new reports in the New York Times, BBC, Reuters and other publications, the authors of the highly controversial French study of rats and biotech foods forced reporters to sign non-disclosure agreements prohibiting journalists from validating the report's findings with independent scientists. Clearly, its authors were concerned that the now-debunked study would wilt under scientific scrutiny, which is exactly what has happened now that the report has been reviewed by independent scientific experts.

According to the BBC:

"In a move regarded as unusual by the media, the French research group refused to provide copies of the journal paper to reporters in advance of its publication, unless they signed non-disclosure agreements. The NDAs would have prevented the journalists from approaching third-party researchers for comment."

The New York Time's Dot Earth blog was even more blunt:

"I have to place it in a big bin of suspect studies "done by people out to prove something rather than investigate something," as the evolutionary biologist Michael Eisen said in a late update to my previous post on this work."

The Yes on Prop 37 campaign was coordinating with the French authors from the very beginning. In fact, within a few hours of the study release, Yes on 37 issued a media advisory announcing a press conference with the study's authors.

"It is clear that this so-called study is nothing more than a propaganda piece intended to create false fear and misinformation to help support the flawed Prop 37 campaign," said No on 37 campaign spokesp
'/>"/>

SOURCE No on Prop. 37
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug
4. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
5. Science study shows promiscuous enzymes still prevalent in metabolism
6. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
9. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
10. Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
11. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Calif., Oct. 10 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... on Monday, October 13, to provide an update on ... stroke.,Hosting the call will be Paul E. Freiman, president ... officer., -- Date: Monday, October 13, ...
... effects of, recombinant lactoferrin (tradename: Lacromin) in mammalian ... leading to a significant boost ... A recently published study,in the scientific journal In Vitro ... see, http://www.Lacromin.com ) is a strong growth factor for ...
... CORPUS CHRISTI, Texas, Oct. 10 CSMG,Technologies, ... management,company, announced the company has received approval ... on a key divisional application for "Bonding ... Electric Current,Therethrough" for CSMG Technologies subsidiary Live ...
Cached Biology Technology:Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... is pleased to name the latest recipients of its ... of Hospital for Special Surgery (HSS), Dipyaman Ganguly, PhD ... of the Feinstein Institute at North Shore-Long Island Jewish ... S.L.E. Lupus Foundation,s lifetime investment in New York City-based ...
... premature aging of immune cells, which may make people more ... new UCSF-led study. The findings indicate that accelerated ... is dependent upon how long someone is depressed, particularly if ... March 2011 by the journal PLoS One and ...
... -- Companies looking to engineer an eco-friendly diesel fuel have ... University researchers, making petroleum diesel completely green would not only ... green. "Fossil fuels are limited, and since we can,t ... are looking for alternative fuel sources like algae," said Peter ...
Cached Biology News:S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research 2S.L.E. Lupus Foundation announces new grants to further NYC scientists' leadership in lupus research 3Study finds link between chronic depression and accelerated immune cell aging 2Study finds link between chronic depression and accelerated immune cell aging 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 2Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 3Economics, physics are roadblocks for mass-scale algae biodiesel production, study finds 4